Logotype for Legend Biotech Corp

Legend Biotech (LEGN) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Legend Biotech Corp

Q3 2026 earnings summary

10 Nov, 2026

Executive summary

  • CARVYKTI net trade sales rose 36% YoY to $710M; Q3 revenue was $359.5M, up 32%, and adjusted net income was $55.6M.

  • FY26 adjusted profitability remains the target; priorities include expanding CARVYKTI access, advancing the pipeline and strengthening execution.

  • Ingrid Zhang became CEO effective September 15, 2026, succeeding interim CEO Alan Bash, who resumed his role as President, CARVYKTI.

Financial highlights

  • Q3 revenue was $359.5M versus $272.4M a year earlier; collaboration revenue was $353.2M, up 35%, and license and other revenue was $6.3M, down 41%.

  • Net income was $51.7M versus a $39.6M loss; adjusted net income was $55.6M versus an $18.7M adjusted loss.

  • Operating expenses fell 18% to $165.1M, including a $24M one-time share-based compensation credit; excluding it, expenses declined 6%.

  • R&D expense declined 16% to $95.3M; SG&A fell 20% to $69.8M, but rose 8% excluding the one-time credit.

  • Adjusted diluted EPS was $0.14 versus $(0.05); IFRS diluted EPS was $0.13 versus $(0.11).

Outlook and guidance

  • FY26 adjusted, company-wide profitability remains the target; CARVYKTI became profitable in 2025 under a product-profit definition based on net trade sales less cost of goods sold and operating expenses.

  • CARVYKTI is expected to deliver double-digit YoY growth in 2027; management described current 2027 sales consensus as high-end relative to anticipated scenarios.

  • 2026 goals include three-quarters of CARVYKTI orders from 2L–4L, LB2501 IND clearance, in vivo data presentation and adjusted profitability.

  • CARTITUDE-5 readout is not expected before 2027; CARTITUDE-6 is expected later. Both studies are event-driven.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Legend Biotech